Surface Oncology’s SRF231 Granted Orphan Drug Status for Treatment of Multiple Myeloma
SRF231, an experimental anti-CD47 immunotherapy candidate developed by Surface Oncology, was granted orphan drug status by the U.S. Food and Drug Administration for the treatment of multiple myeloma. The designation is granted by the FDA’s Office of Orphan Products Development (OOPD) to investigational therapies intended to…